Synapse - Breast Medicine Service

Results (4181)

A phase 1/1b study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib in patients with estrogen receptor-positive (ER+) advanced breast cancer (ABC) who had progressed after endocrine therapy (ET)

Meeting Abstract

Jhaveri, K.; Juric, D.; Cresta, S.; Yap, Y. S.; Duhoux, F. P.; Terret, C.; Layman, R.; Kundamal, N.; Liao, S.; Ji, Y.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer

Meeting Abstract

Jhaveri, K.; Kalinsky, K.; Bedard, P.; Cervantes, A.; Saura, C.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; more...
Cancer Research (2020)

Fulltext@MSK | Save

A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER(+)) HER2-negative (HER2(-)) metastatic breast cancer

Meeting Abstract

Jhaveri, K.; Winer, E. P.; Lim, E.; Fidalgo, J. A. P.; Bellet, M.; Mayer, I. A.; Boni, V.; Patel, J. M.; Bardia, A.; Garcia, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Surgical decision making and clinical outcomes in breast cancer (BC) patients (pts) with germline alterations in moderate risk BC susceptibility genes (CHEK2, PALB2 and ATM)

Meeting Abstract

dos Anjos, C. H.; Amoros, K.; Pilewskie, M.; Braunstein, L.; Robson, M.
Cancer Research (2020)

Fulltext@MSK | Save

Real-world predictors of first-line treatment and descriptive outcomes in HR(+)/HER2(-) metastatic breast cancer patients in the US

Meeting Abstract

Downer, M. K.; Jhaveri, K.; Bardia, A.; Loi, S.; Kent, M.; Luhn, P.; Humke, E. W.
Cancer Research (2020)

Fulltext@MSK | Save

Polygenic breast cancer risk modification in carriers of high and intermediate risk gene mutations

Meeting Abstract

Gallagher, S.; Hughes, E.; Wagner, S.; Tshiaba, P.; Rosenthal, E.; Roa, B. B.; Kurian, A.; Domchek, S.; Garber, J.; Lancaster, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Genomic profiling of primary and metastatic breast cancer in men

Meeting Abstract

Drago, J. Z.; Serna-Tamayo, C.; Dos Anjos, C. H.; Brown, D. N.; Modi, S.; Jhaveri, K.; Solit, D. B.; Traina, T. A.; Chandarlapaty, S.; Reis-Filho, J. S.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Mechanisms of resistance to CDK4/6 inhibitors and new therapeutic approaches

Meeting Abstract

Chandarlapaty, S.
Cancer Research (2020)

Fulltext@MSK | Save

ER pathway activity signature as a biomarker for endocrine agent GDC-9545

Meeting Abstract

Daemen, A.; Spoerke, J. M.; Zhou, W.; Guan, J.; Ingalla, E.; Young, A.; Hafner, M.; Aimi, J.; Chang, C. W.; Giltnane, J. M.; more...
Cancer Research (2020)

Fulltext@MSK | Save

Phase 1/2 dose-escalation and expansion study investigating SAR439859, a potent, oral, selective estrogen receptor degrader, +/- palbociclib in metastatic breast cancer

Meeting Abstract

Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Celanovic, M.; Linden, H. M.
Cancer Research (2020)

Fulltext@MSK | Save